Journal of Human Genetics (2016) 61, 771–772

www.nature.com/jhg

CORRIGENDUM

Corrigendum: Analysis of the genes responsible for steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis in Japanese patients by whole-exome sequencing analysis

Daisuke Ogino, Taeko Hashimoto, Motoshi Hattori, Noriko Sugawara, Yuko Akioka, Gen Tamiya, Satoshi Makino, Kentaro Toyota, Tetsuo Mitsui and Kiyoshi Hayasaka

Journal of Human Genetics (2016) **61,** 771–772; doi:10.1038/jhg.2016.31

Correction to: *Journal of Human Genetics* (2016) **61,** 137–141; doi:10.1038/jhg.2015.122; Published online 15 October 2015.

Since the publication of the above article, the authors have noticed an error in the description of mutation.

The *LAMB2* mutation in Case 12 described as c.1405+1g>a (splicing mutation) in the main text and Tables 1 and 2 should have been c.1406g>a (p.R469Q). Case 12 was a compound heterozygote of *LAMB2* p.[R469Q];[G699R] mutation.

This correction does not alter the results, but the sentence 'The homozygous c. [1405+1g>a] mutation was reported in the patient showing Pierson syndrome.' in the Discussion should have been deleted.

The authors would like to apologize for this mistake.

Table 1 Nucleotide changes detected in 24 patients with FSGS and/or SRNS from 22 different families

No	*Gene*	*Mutation*		*Status*	*PolyPhen-2 (HumDiv)*	*PolyPhen-2 (HumVar)*	*Grantham score*	*PhastCons score*	*GERP score*	*References and information*
1	*PTPRO*	c.1013c>t	p.S338F	Heterozygote	1	0.998	155	0.996	5.23	rs.200478856
6	*NPHS1*	c.656c>t	p.A219V	Heterozygote	0.692	0.148	64	0.334	–0.75	Sibling of case 7 rs.757417823
7	*NPHS1*	c.656c>t	p.A219V	Heterozygote	0.692	0.148	64	0.334	–0.75	Sibling of case 6 rs.757417823
15	*NPHS2*	c.412c>t	p.R138X	Heterozygote	NA	NA	NA	1	4.91	
		c.503g>a	p.R168H	Heterozygote	1	0.999	29	1	4.52	
22	*NPHS2*	c.860a>g	p.Q287R	Heterozygote	0.989	0.979	43	1	5.34	rs.200042397
12	*LAMB2*	c.1406g>a	p.R469Q[a]	Heterozygote	0.996	0.755	43	0.719	3.44	
		c.2095g>c	p.G699R	Heterozygote	0.986	0.593	125	0.992	5.49	rs.28364667
10	*CD2AP*	c.221g>t	p.R74M[a]	Heterozygote	0.966	0.641	91	1	4.65	
11	*CD2AP*	c.221g>t	p.R74M[a]	Heterozygote	0.966	0.641	91	1	4.65	
16	*TRPC6*	c.2624a>t	p.E875V[a]	Heterozygote	1	0.982	121	1	5.89	
19	*WT1*	c.421a>c	p.K141Q[a]	Heterozygote	0.960	0.545	53	1	2.58	Daughter of case 20
		c.745c>a	p.P249T[a]		0.035	0.027	38	1	5.62	
20	*WT1*	c.421a>c	p.K141Q[a]	Heterozygote	0.960	0.545	53	1	2.58	Mother of case 19
		c.745c>a	p.P249T[a]		0.035	0.027	38	1	5.62	
24	*INF-2*	c.550g>a	p.E184K	Heterozygote	1	0.999	56	0.709	4.48	

Abbreviations: FSGS, focal glomerular sclerosis; GFRP, Genomic Evolutionary Rate Profiling; NA, not analyzed; SRNS, steroid-resistant nephrotic syndrome.
[a]Novel mutations.

Table 2 Gene mutations and clinical features

No	Sex	Age at onset	Response for treatment	Pathology	Prognosis	Age at ESRF	Gene	Causative or predisposing mutation		Clinical features
15	M	At birth	No trials	FSGS	ESRF	11y3m	*NPHS2*	c.[412c>t]; [503g>a]	p.[R138X]; [R168H]	No relapse after renal transplantation at age 11y4m Sister with FSGS died of renal failure at age 5
12	M	1y9m	Resistant	FSGS	ESRF	2y2m	*LAMB2*	c.[1406g>a]; [2095g>c]	p.[R469Q[a]]; [G699R]	No relapse after renal transplantation at age 7y2m No ocular symptoms No affected family members
10	M	5y4m	Initially responsive	FSGS	ESRF	7y6m	*CD2AP*	c.221g>t	p.R74M[a]	FSGS relapsed after renal transplantation at age 8y1m No affected family members
11	M	5y2m	Responsive Frequently relapse	FSGS	Complete remission	—	*CD2AP*	c.221g>t	p.R74M[a]	No affected family members
16	F	12y5m	Resistant	FSGS	ESRF	23y11m	*TRPC6*	c.2624a>t	p.E875V[a]	hemodialysis at age 23 Father had proteinuria; grandfather died of renal disease at age 30.
19	F	6y7m	No trials	FSGS	ESRF	16y6m	*WT1*	c. [421a>c; 745 c>a]	p.[K141Q[a]; P249T[a]]	Daughter of case 20; bicornuate uterus Grandfather died of renal disease at age 42
20	F	10y	Unknown	NA	ESRF	42y	*WT1*	c. [421a>c; 745 c>a]	p.[K141Q[a]; P249T[a]]	Mother of case 19; bicornuate uterus Father died of renal disease at age 42
24	M	10y	Resistant	FSGS	ESRF	16y11m	*INF-2*	c.550g>a	p.E184K	No relapse after renal transplantation at age 20 No affected family members

Abbreviations: ESRF, end-stage renal failure; FSGS, focal glomerular sclerosis; m, months; NA, not analyzed; y, years.
[a]Novel mutations.